09:20 AM EDT, 07/02/2024 (MT Newswires) -- Legend Biotech ( LEGN ) said Tuesday that a late-stage study of its drug Carvykti showed positive overall survival results over other treatments in adult patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three previous treatments.

The company said the study evaluated the safety and efficacy of Carvykti compared with pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide, and dexamethasone.

Legend said Carvykti showed "statistically significant and clinically meaningful improvement in overall survival" in the second interim analysis of the trial.

The company said the study's results supported the US Food and Drug Administration's April 5 approval of Carvykti.

Price: 45.99, Change: -0.03, Percent Change: -0.07